Published in Br J Clin Pharmacol on October 01, 2014
Guidance for the treatment of deep vein thrombosis and pulmonary embolism. J Thromb Thrombolysis (2016) 0.96
Successful resolution of a left ventricular thrombus with apixaban treatment following acute myocardial infarction. Heart Vessels (2014) 0.91
Cardiovascular safety of new oral anticoagulants: re-analysis of 27 randomized trials based on Bayesian network meta-analysis. Br J Clin Pharmacol (2015) 0.78
Prescription patterns of oral anticoagulants for patients with non-valvular atrial fibrillation: experience at a Japanese single institution. Heart Vessels (2015) 0.77
Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulants. Clin Interv Aging (2015) 0.76
Efficacy, safety and administration timing of trastuzumab in human epidermal growth factor receptor 2 positive breast cancer patients: A meta-analysis. Exp Ther Med (2016) 0.75
Bleeding outcomes associated with rivaroxaban and dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis. BMC Cardiovasc Disord (2017) 0.75
Potential use of NOACs in developing countries: pros and cons. Eur J Clin Pharmacol (2014) 0.75
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med (2012) 11.86
Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97
Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med (2010) 9.92
Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med (2009) 9.17
The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol (1997) 9.01
Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med (2011) 7.30
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet (2009) 6.83
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med (2013) 6.71
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med (2008) 6.32
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med (2008) 6.00
Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med (2010) 5.59
Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med (2012) 5.56
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet (2007) 5.41
Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med (2011) 4.81
Apixaban for extended treatment of venous thromboembolism. N Engl J Med (2012) 4.37
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost (2007) 3.66
Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol (2012) 3.55
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet (2010) 3.29
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet (2009) 3.13
Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med (2009) 2.90
Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost (2011) 2.53
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty (2008) 2.30
Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J (2011) 2.21
Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol (2011) 1.92
Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation (2012) 1.83
The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost (2007) 1.73
Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis. BMJ (2012) 1.33
Dabigatran's 'real-world' data about risk of myocardial infarction and gastrointestinal bleeding contradicts with randomized trials. J Am Coll Cardiol (2013) 1.12
Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison. J Clin Pharm Ther (2011) 1.01
Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials. BMJ Open (2012) 0.87
Anticoagulation therapy. Dabigatran and risk of myocardial infarction. Nat Rev Cardiol (2012) 0.84
Treatment with an oral direct thrombin inhibitor decreases platelet activity but increases markers of inflammation in patients with myocardial infarction. J Intern Med (2011) 0.83
Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ (2011) 4.05
Value of severity scales in predicting mortality from community-acquired pneumonia: systematic review and meta-analysis. Thorax (2010) 2.20
Postthrombolysis intracranial hemorrhage risk of cerebral microbleeds in acute stroke patients: a systematic review and meta-analysis. Int J Stroke (2012) 1.98
Association of obstructive sleep apnea with risk of serious cardiovascular events: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes (2012) 1.76
Meta-analysis: risk of fractures with acid-suppressing medication. Bone (2010) 1.57
Statins and associated risk of pneumonia: a systematic review and meta-analysis of observational studies. Eur J Clin Pharmacol (2011) 1.46
Bone mineral density and incidence of stroke: European prospective investigation into cancer-norfolk population-based study, systematic review, and meta-analysis. Stroke (2014) 1.00
Body fat percentage, body mass index and waist-to-hip ratio as predictors of mortality and cardiovascular disease. Heart (2014) 0.96
Functional polymorphisms of folate metabolism and response to chemotherapy for colorectal cancer, a systematic review and meta-analysis. Pharmacogenet Genomics (2012) 0.91
The International Community-Acquired Pneumonia (CAP) Collaboration Cohort (ICCC) study: rationale, design and description of study cohorts and patients. BMJ Open (2012) 0.86
The SOAR (Stroke subtype, Oxford Community Stroke Project classification, Age, prestroke modified Rankin) score strongly predicts early outcomes in acute stroke. Int J Stroke (2013) 0.86
Relative effects of two different enoxaparin regimens as comparators against newer oral anticoagulants: meta-analysis and adjusted indirect comparison. Chest (2013) 0.78
Prognostic value of troponins in acute coronary syndrome depends upon patient age. Heart (2014) 0.78
Response to Chandra et al., and Freedberg and Abrams. Am J Gastroenterol (2013) 0.75
The thorough QT study - do we need more of the same? Br J Clin Pharmacol (2016) 0.75
Do physiological scoring and a novel point of care metabolic screen predict 48-h outcome in admissions from the emergency department resuscitation area? Eur J Emerg Med (2016) 0.75